Drugs in R&D

Papers
(The H4-Index of Drugs in R&D is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells63
Pexidartinib (TURALIOâ„¢): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor35
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment31
Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety29
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis29
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study26
Potential for the Repurposing of Adamantane Antivirals for COVID-1922
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor20
Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System19
Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus18
Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis17
NLRP3 Inhibitor Tranilast Attenuates Gestational Diabetes Mellitus in a Genetic Mouse Model15
Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials14
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp14
0.021169185638428